Kim Fox

Summary

Affiliation: Royal Brompton Hospital
Country: UK

Publications

  1. ncbi request reprint Resting heart rate in cardiovascular disease
    Kim Fox
    Royal Brompton Hospital, Sydney Street, London SW3 6NP, England
    J Am Coll Cardiol 50:823-30. 2007
  2. doi request reprint Effect of ivabradine in patients with left-ventricular systolic dysfunction: a pooled analysis of individual patient data from the BEAUTIFUL and SHIFT trials
    Kim Fox
    NHLI Imperial College and ICMS, Royal Brompton Hospital, Sydney Street, London SW3 6NP, UK
    Eur Heart J 34:2263-70. 2013
  3. ncbi request reprint Rationale and design of a randomized, double-blind, placebo-controlled trial of ivabradine in patients with stable coronary artery disease and left ventricular systolic dysfunction: the morBidity-mortality EvAlUaTion of the I(f) inhibitor ivabradine in pa
    Kim Fox
    Royal Brompton Hospital, Sydney Street, London, UK
    Am Heart J 152:860-6. 2006
  4. doi request reprint Relationship between ivabradine treatment and cardiovascular outcomes in patients with stable coronary artery disease and left ventricular systolic dysfunction with limiting angina: a subgroup analysis of the randomized, controlled BEAUTIFUL trial
    Kim Fox
    Royal Brompton Hospital, Sydney Street, London, UK
    Eur Heart J 30:2337-45. 2009
  5. ncbi request reprint [Guidelines on the management of stable angina pectoris; the experts of the European Society of Cardiology on the management of stable angina pectoris]
    Kim Fox
    Department of Cardiology, Royal Brompton Hospital, Sydney Street, London SW3 6NP, UK
    Kardiol Pol 64:823-80. 2006
  6. ncbi request reprint Guidelines on the management of stable angina pectoris: executive summary: The Task Force on the Management of Stable Angina Pectoris of the European Society of Cardiology
    Kim Fox
    Department of Cardiology, Royal Brompton Hospital, London, UK
    Eur Heart J 27:1341-81. 2006
  7. ncbi request reprint Selective and specific I(f) inhibition: new perspectives for the treatment of stable angina
    Kim Fox
    Royal Brompton Hospital, Sydney Street, London, SW3 6NP, UK
    Expert Opin Pharmacother 7:1211-20. 2006
  8. ncbi request reprint Should angiotensin-converting enzyme-inhibitors be used to improve outcome in patients with coronary artery disease and 'preserved' left ventricular function?
    Kim Fox
    Department of Cardiology, Royal Brompton Hospital, Sydney Street, London SW3 6NP, UK
    Eur Heart J 27:2154-7. 2006
  9. ncbi request reprint 64-multislice computed tomography in consecutive patients with suspected or proven coronary artery disease: initial single center experience
    Carmine Musto
    Royal Brompton Hospital, Sydney Street, SW3 6NP, London, United Kingdom
    Int J Cardiol 114:90-7. 2007
  10. ncbi request reprint Differences in presentation and management of stable angina from East to West in Europe: a comparison between Poland and the UK
    Caroline Ann Daly
    Royal Brompton Hospital, Sydney St London SW3 6NP, UK
    Int J Cardiol 125:311-8. 2008

Detail Information

Publications21

  1. ncbi request reprint Resting heart rate in cardiovascular disease
    Kim Fox
    Royal Brompton Hospital, Sydney Street, London SW3 6NP, England
    J Am Coll Cardiol 50:823-30. 2007
    ..These findings suggest that the potential role of HR and its modulation should be considered in future cardiovascular guidance documents...
  2. doi request reprint Effect of ivabradine in patients with left-ventricular systolic dysfunction: a pooled analysis of individual patient data from the BEAUTIFUL and SHIFT trials
    Kim Fox
    NHLI Imperial College and ICMS, Royal Brompton Hospital, Sydney Street, London SW3 6NP, UK
    Eur Heart J 34:2263-70. 2013
    ..To test the effect of ivabradine on the outcomes in a broad population with left-ventricular (LV) systolic dysfunction with coronary artery disease (CAD) and/or heart failure (HF)...
  3. ncbi request reprint Rationale and design of a randomized, double-blind, placebo-controlled trial of ivabradine in patients with stable coronary artery disease and left ventricular systolic dysfunction: the morBidity-mortality EvAlUaTion of the I(f) inhibitor ivabradine in pa
    Kim Fox
    Royal Brompton Hospital, Sydney Street, London, UK
    Am Heart J 152:860-6. 2006
    ..Because patients with coronary artery disease and left ventricular dysfunction are at high risk of cardiac events and death, we hypothesized that they could derive particular benefit from a specific HR-lowering agent such as ivabradine...
  4. doi request reprint Relationship between ivabradine treatment and cardiovascular outcomes in patients with stable coronary artery disease and left ventricular systolic dysfunction with limiting angina: a subgroup analysis of the randomized, controlled BEAUTIFUL trial
    Kim Fox
    Royal Brompton Hospital, Sydney Street, London, UK
    Eur Heart J 30:2337-45. 2009
    ..We performed a post hoc analysis of the effect of ivabradine in BEAUTIFUL patients whose limiting symptom at baseline was angina, particularly in terms of coronary outcomes...
  5. ncbi request reprint [Guidelines on the management of stable angina pectoris; the experts of the European Society of Cardiology on the management of stable angina pectoris]
    Kim Fox
    Department of Cardiology, Royal Brompton Hospital, Sydney Street, London SW3 6NP, UK
    Kardiol Pol 64:823-80. 2006
  6. ncbi request reprint Guidelines on the management of stable angina pectoris: executive summary: The Task Force on the Management of Stable Angina Pectoris of the European Society of Cardiology
    Kim Fox
    Department of Cardiology, Royal Brompton Hospital, London, UK
    Eur Heart J 27:1341-81. 2006
  7. ncbi request reprint Selective and specific I(f) inhibition: new perspectives for the treatment of stable angina
    Kim Fox
    Royal Brompton Hospital, Sydney Street, London, SW3 6NP, UK
    Expert Opin Pharmacother 7:1211-20. 2006
    ..It offers clear therapeutic benefits for a whole range of patients with stable angina, including those with contraindications or intolerance to beta-blockers...
  8. ncbi request reprint Should angiotensin-converting enzyme-inhibitors be used to improve outcome in patients with coronary artery disease and 'preserved' left ventricular function?
    Kim Fox
    Department of Cardiology, Royal Brompton Hospital, Sydney Street, London SW3 6NP, UK
    Eur Heart J 27:2154-7. 2006
    ....
  9. ncbi request reprint 64-multislice computed tomography in consecutive patients with suspected or proven coronary artery disease: initial single center experience
    Carmine Musto
    Royal Brompton Hospital, Sydney Street, SW3 6NP, London, United Kingdom
    Int J Cardiol 114:90-7. 2007
    ..The aim of the present study was to assess the clinical usefulness of in consecutive patients with suspected or proven coronary artery disease (CAD)...
  10. ncbi request reprint Differences in presentation and management of stable angina from East to West in Europe: a comparison between Poland and the UK
    Caroline Ann Daly
    Royal Brompton Hospital, Sydney St London SW3 6NP, UK
    Int J Cardiol 125:311-8. 2008
    ..The aim of this study was to compare the presentation of stable angina to cardiology services in Poland vs. the United Kingdom, the management of the condition in relation to existing European guidelines and clinical outcome...
  11. ncbi request reprint Efficacy of ivabradine, a new selective I(f) inhibitor, compared with atenolol in patients with chronic stable angina
    Jean Claude Tardif
    Montreal Heart Institute, 5000 Belanger Street, Montreal, Quebec H1T 1C8, Canada
    Eur Heart J 26:2529-36. 2005
    ..Ivabradine has shown anti-ischaemic and anti-anginal activity in a placebo-controlled trial. The objective of this study was to compare the anti-anginal and anti-ischaemic effects of ivabradine and the beta-blocker atenolol...
  12. doi request reprint Ivabradine for patients with stable coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a randomised, double-blind, placebo-controlled trial
    Kim Fox
    Royal Brompton Hospital, London, UK
    Lancet 372:807-16. 2008
    ..We aimed to test whether lowering the heart rate with ivabradine reduces cardiovascular death and morbidity in patients with coronary artery disease and left-ventricular systolic dysfunction...
  13. doi request reprint Heart rate as a prognostic risk factor in patients with coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a subgroup analysis of a randomised controlled trial
    Kim Fox
    Royal Brompton Hospital, London, UK
    Lancet 372:817-21. 2008
    ..We did a subanalysis of this placebo group to test the hypothesis that elevated resting heart rate at baseline is a marker for subsequent cardiovascular death and morbidity...
  14. pmc Angina, "normal" coronary angiography, and vascular dysfunction: risk assessment strategies
    Raffaele Bugiardini
    Department of Internal Medicine, Cardio Angiology and Hepatology, University of Bologna, Bologna, Italy
    PLoS Med 4:e12. 2007
  15. ncbi request reprint [Guidelines on the management of stable angina pectoris. Executive summary]
    Kim Fox
    Sociedad europea de cardiologia
    Rev Esp Cardiol 59:919-70. 2006
  16. pmc Cost effectiveness of perindopril in reducing cardiovascular events in patients with stable coronary artery disease using data from the EUROPA study
    Andrew Briggs
    Public Health and Health Policy, University of Glasgow, Glasgow, UK
    Heart 93:1081-6. 2007
    ..The EUropean trial on Reduction Of cardiac events with Perindopril in stable coronary Artery disease (EUROPA) trial has recently reported...
  17. ncbi request reprint [Guidelines on the management of stable angina pectoris: executive summary]
    Kim Fox
    G Ital Cardiol (Rome) 7:535-83. 2006
  18. ncbi request reprint Antianginal and antiischemic effects of ivabradine, an I(f) inhibitor, in stable angina: a randomized, double-blind, multicentered, placebo-controlled trial
    Jeffrey S Borer
    Weill Medical College of Cornell University, New York, NY, USA
    Circulation 107:817-23. 2003
    ..This study evaluated the antianginal and antiischemic effects of ivabradine, a new heart rate-lowering agent that acts specifically on the sinoatrial node...
  19. ncbi request reprint Treatment benefit by perindopril in patients with stable coronary artery disease at different levels of risk
    Jaap W Deckers
    Department of Cardiology, Thoraxcenter, Erasmus University Medical Center Rotterdam, The Netherlands
    Eur Heart J 27:796-801. 2006
    ..We developed a cardiovascular risk model based on the EUROPA study population and investigated whether benefit of long-term administration of the angiotensin-converting enzyme (ACE)-inhibitor perindopril was modified by risk level...
  20. ncbi request reprint Heart rate: a risk factor for cardiac diseases and outcomes? Pathophysiology of cardiac diseases and the potential role of heart rate slowing
    Gaetano Antonio Lanza
    Cardiology Institute, Catholic University of the Sacred Heart, Rome, Italy
    Adv Cardiol 43:1-16. 2006
    ..Thus, a reduction of HR might have direct beneficial clinical effects, as also suggested by experimental findings...
  21. ncbi request reprint Angiotensin-converting-enzyme inhibitors in stable vascular disease without left ventricular systolic dysfunction or heart failure: a combined analysis of three trials
    Gilles R Dagenais
    The Laval University Heart and Lung Institute, Laval Hospital, Quebec, Canada G1V 4G5
    Lancet 368:581-8. 2006
    ....